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Infection of hepatocytes by Plasmodium falciparum
sporozoites requires the host tetraspanin CD81.
CD81 is also predicted to be a coreceptor, along
with scavenger receptor BI (SR-BI), for hepatitis C
virus. Using SR-BI-knockout, SR-BI-hypomorphic
and SR-BI-transgenic primary hepatocytes, as well
as specific SR-BI-blocking antibodies, we demon-
strate that SR-BI significantly boosts hepatocyte
permissiveness to P. falciparum,P. yoelii, andP. ber-
ghei entry and promotes parasite development. We
show that SR-BI, but not the low-density lipoprotein
receptor, acts as a major cholesterol provider that
enhances Plasmodium infection. SR-BI regulates
the organization of CD81 at the plasma membrane,
mediating an arrangement that is highly permissive
to penetration by sporozoites. Concomitantly, SR-
BI upregulates the expression of the liver fatty-acid
carrier L-FABP, a protein implicated in Plasmodium
liver-stage maturation. These findings establish the
mechanistic basis of the CD81-dependent Plasmo-
dium sporozoite invasion pathway.
INTRODUCTION
Malaria remains the principal parasitic human disease, responsi-
ble for more than one million deaths annually. Malaria is initiated
by the inoculation of Plasmodium sporozoites into the mamma-
lian host by a female Anopheles mosquito. After entry into blood
capillaries, some of these sporozoites are transported in the
bloodstream to the liver, where they specifically invade hepato-
cytes by forming a membrane-bound compartment called theCell Host &parasitophorous vacuole in which the parasite resides for further
intracellular development (Prudencio et al., 2006; Sturm et al.,
2006). The parasite then differentiates into replicative exoeryth-
rocytic forms (EEFs) that will ultimately give rise to thousands
of merozoites that initiate the pathogenic erythrocytic cycle.
On the other hand, the hepatotropic virus called hepatitis C virus
(HCV) causes hepatitis C, which is a blood-borne infectious
disease resulting in serious outcomes such as chronic hepatitis,
cirrhosis, and hepatocarcinoma. These two major human patho-
gens, hepatitis C virus and the P. falciparum sporozoite, com-
monly target the hepatocyte and infect it via an invasion pathway
comparable in many regards.
Thus, heparan sulfate might serve as the initial docking site for
HCV attachment (Barth et al., 2003) and for the initial sequestra-
tion of Plasmodium sporozoites in the liver sinusoids (Muller
et al., 1993; Sinnis et al., 1996). In addition, hepatocyte permis-
siveness to these two pathogens is tetraspanin CD81 depen-
dent. CD81 functions as an entry HCV coreceptor, although
one or more unidentified hepatocyte-specific molecules could
act as the primary attachment receptor, thereby accounting for
the restricted tropism of HCV (Pileri et al., 1998). Infection of
hepatocytic cells by sporozoites of P. falciparum and P. yoelii
species is also strictly CD81 dependent (Silvie et al., 2006b; Sil-
vie et al., 2003; Yalaoui et al., 2008). Biochemical studies suggest
that tetraspanins function as molecular organizers of the mem-
brane collectively referred to as the tetraspanin web (Rubinstein
et al., 1996). Tetraspanins self-associate to form specific proteo-
lipidic membrane microdomains. In these microdomains, CD81
associates with cholesterol and other tetraspanins such as
CD9. Cellular cholesterol is critical for the infectivity of both
HCV virus (Kapadia et al., 2007; Zhang et al., 2004) and the
Plasmodium sporozoite (Silvie et al., 2006a).
In addition to CD81, three other proteins expressed at the
hepatocyte membrane have been identified as potential HCV
coreceptors. Thus, claudin-1 is required for a late step in HCVMicrobe 4, 283–292, September 11, 2008 ª2008 Elsevier Inc. 283
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invasion (S.Y. et al., unpublished data). Furthermore, two lipo-
protein receptors involved in cholesterol uptake, the scavenger
receptor B type I (SR-BI) (Scarselli et al., 2002) and the low-den-
sity lipoprotein receptor (LDLR) (Agnello et al., 1999), have also
been proposed as putative candidate receptors for HCV.
Lipoproteins have also been shown to be linked to Plasmodium
invasion (Sinnis et al., 1996).
SR-BI is a highly glycosylated 82–85 kDa membrane protein
that is expressed in several cell types, including hepatocytes,
Ku¨pffer, and hepatic sinusoidal endothelial cells. SR-BI facili-
tates the bidirectional movement of cholesterol between cells
and lipoprotein particles; more specifically, SR-BI mediates
selective cellular uptake of cholesteryl esters from both high-
(Acton et al., 1996; Rhainds and Brissette, 2004; Truong et al.,
2000) and low-density lipoproteins (Rhainds et al., 2003), HDL
and LDL respectively.
In contrast to HCV infection whose study is restricted to hu-
man cells, the Plasmodium invasion pathway can be explored
in mice using murine Plasmodium species. The recent develop-
ment of SR-BI-deficient mice (SR-BI/) (Huby et al., 2006)
offered the opportunity to study the requirement of SR-BI in
the invasion process of the Plasmodium sporozoite. Here, we
investigated the role of SR-BI in hepatocyte permissiveness to
Plasmodium infection by using human hepatocytes as well as
murine primary hepatocytes displaying differences in levels of
SR-BI expression. We demonstrated that SR-BI significantly
boosts hepatocyte permissiveness to P. falciparum, P. yoelii,
and P. berghei entry and promotes parasite development.
RESULTS
SR-BI Boosts Sporozoite Entry into the Hepatocyte
We first investigated whether SR-BI contributes to hepatocyte
infection by the Plasmodium sporozoite. Primary hepatocytes
isolated from LDLR/, SR-BI/, hypomorphic-SR-BI and SR-
BI-transgenic mice were tested for permissiveness to P. yoelii
265BY (Figure 1A) and 17XNL strains (Figure S1 available online)
and to P. berghei (Figure 1B). Lack of SR-BI resulted in a residual
hepatocyte permissiveness of 22% ± 5% when compared to
wild-type or to LDLR/ cells, whereas hypomorphic-SR-BI he-
patocytes weakly expressing SR-BI (Huby et al., 2006) (10% of
the level in wild-type cells) were slightly more permissive (37% ±
10%). SR-BI-transgenic hepatocytes displaying a 3-fold
SR-BI overexpression revealed an enhanced permissiveness
(125% ± 12%) when compared to wild-type cells.
The contribution of SR-BI to the sporozoite entry into target
cells was then evaluated by double immunostaining of P. yoelii
parasites 3 hr after sporozoite addition. A marked reduction in
the number of intracellular parasites was observed in SR-BI/
(65%) and hypomorphic-SR-BI hepatocytes, whereas SR-BI
overexpression facilitated the sporozoite entry by 25%, as
compared to wild-type cells (Figure 1A). Attachment of the spo-
rozoite at the surface of the hepatocyte was independent of the
SR-BI expression level (Figure S2). The lack of LDLR had no im-
pact on parasite entry. The LDLR is a mosaic protein that medi-
ates endocytosis of cholesterol-rich LDL particles; cholesterol is
then delivered to the endoplasmic reticulum (ER). Because the
lack of SR-BI might not account for its absence only at the cell284 Cell Host & Microbe 4, 283–292, September 11, 2008 ª2008 ElFigure 1. SR-BI Boosts Hepatocyte Permissiveness to Plasmodium
Entry and Infection
(A) Primary hepatocytes isolated from SR-BI/, hypomorphic-SR-BI, SR-BI-
transgenic, and LDLR/ mice were infected with P. yoelii 265BY and cultured
for 48 hr before EEF quantification (black bars). P. yoelii entry was also evalu-
ated 3 hr after infection with a double immunostaining of the sporozoite (white
bars). EEFs and penetration rates are expressed relative to those in wild-type
hepatocytes. Means of schizont numbers per well in controls of three indepen-
dent experiments were as follows: wtEEFs, 994, 1425, and 2011; wtentry, 241,
623, and 704.
(B) On the left, primary hepatocytes isolated from SR-BI/, hypomorphic-
SR-BI, and SR-BI-transgenic mice were infected with P. berghei and cultured
for 48 hr before EEF quantification. Means of schizont numbers per well in
controls of three independent experiments were as follows: wtEEFs-P. berghei,
117, 325, and 598. EEFs are expressed relative to those in wild-type hepato-
cytes. On the right, mouse wild-type hepatocytes were incubated with the
specific SR-BI antibody for 9 hr (t6h to t+3h), 6 hr (t3h to t+3h), 3 hr (t0h to
t+3h), or 45 hr (t+3h to t+48h). Cells were inoculated with P. berghei sporozoites
at t0h, washed at t+3h, and cultured until EEF quantification at t48h. EEFs are
expressed relative to those in nontreated hepatocytes. Means of schizont
numbers per well in controls of three independent experiments were as
follows: wtEEFs-P. berghei, 152, 394, and 554.
(C and D) Mouse (C) or human (D) wild-type hepatocytes were incubated with
the specific SR-BI antibody for 9 hr (t6h to t+3h), 6h (t-3h to t+3h), 3 hr (t0h to t+3h),
or 45 hr (t+3h to t+48h). Cells were inoculated with P. yoelii 265BY or P. falcipa-
rum sporozoites at t0h, washed at t+3h, and cultured until EEF quantification at
t48h or t120h, respectively. EEFs are expressed relative to those in nontreated
hepatocytes. Means of schizont numbers per well in controls of three indepen-
dent experiments were as follows: wtEEFs-P. yoelii, 402, 808, and 1,697;
wtEEFs-P. falciparum, 316, 767, and 903. Analyses were carried out in triplicate
wells. Data are representative of three independent experiments. Results
are expressed as mean ± standard deviation. *p < 0.05 and **p < 0.001 as
compared with controls.sevier Inc.
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or human liver tissue were infected in vitro with P. berghei,
P. yoelii, or P. falciparum sporozoites, respectively, in the pres-
ence of species-specific SR-BI-blocking antibodies (Figures
1B–1D). The antibody was added at various times before or after
sporozoite addition. Parasites were centrifuged to interact im-
mediately with target cells. No inhibition of Plasmodium infection
was seen when antibodies and parasites were added together to
target cells or when antibodies were loaded onto Plasmodium-
infected hepatocytes 3 hr after sporozoite addition. In contrast,
preincubation of cells with the specific SR-BI-blocking antibody
for 6 hr resulted in 67%–77% inhibition with the three Plasmo-
dium species. Such residual infection was of the same magni-
tude as that observed in SR-BI/ cells, thereby suggesting
that SR-BI antibodies were fully efficient in blocking SR-BI. The
SR-BI-blocking antibody directed to human SR-BI was shown
previously to partially inhibit both serum-derived HCV binding
to human hepatoma cells (Maillard et al., 2006) and the infectivity
of cell culture and plasma-derived HCVcc (Grove et al., 2007).
Preincubation of sporozoites with SR-BI-antibodies was without
effect on Plasmodium infection, demonstrating the absence of
toxicity on the parasite. Considered together, these data indicate
not only that SR-BI must be blocked for several hours before the
parasite-target cell encounter to lead to a major inhibition of in-
fection but also that SR-BI located at the plasma membrane
boosts sporozoite entry into the hepatocyte.
Cell Cholesterol Depletion after SR-BI Deficiency
Impacts Hepatocyte Permissiveness to Plasmodium
The fact that SR-BI mediates selective cholesteryl ester (CE)
uptake from lipoproteins at the cell surface leads us to evaluate
the cholesterol content of SR-BI-deficient hepatocytes. A
40% cholesterol depletion was observed in SR-BI/ and
hypomorphic-SR-BI hepatocytes, respectively (Figure 2A). Free
cholesterol and CE were comparably affected, whereas the
plasma-membrane cholesterol could be reduced by 57%.
Furthermore, a 6 hr preincubation of wild-type murine hepato-
cytes with the specific SR-BI-blocking mAb caused cellular
cholesterol content to fall to a level (60%/nontreated cells) close
to that in SR-BI/ hepatocytes (Figure 2D). Thus, blockage of
SR-BI at the cell membrane could mimic the absence of the
SR-BI gene. Overexpression of SR-BI or absence of the LDLR
had no significant impact on cellular cholesterol content
(Figure 2A).
To test whether the poor permissiveness of hepatocytes lack-
ing SR-BI to sporozoites was due solely to cholesterol depletion,
cholesterol was delivered to SR-BI/ cells through the addition
of preformed MbCD-cholesterol complexes, which are known
to replenish cells with cholesterol after depletion or to enrich
non-cholesterol-depleted cells (Silvie et al., 2007). Cholesterol
analysis of SR-BI/ hepatocytes 3 hr after treatment with
MbCD-cholesterol complexes (10 mM MbCD/1 mM cholesterol)
showed that the total cholesterol, free cholesterol, and CE in
whole cells were enhanced to90% of that in wild-type hepato-
cytes and that the plasma membrane cholesterol was fully re-
covered (Figure 2A). In contrast, hepatocyte permissiveness to
P. yoelii was increased modestly to 41% ± 10% relative to the
control (Figure 2B). We have demonstrated here that cholesterol
uptake via SR-BI facilitates sporozoite entry through the plasmaCell Host &Figure 2. Role of SR-BI in Cell Cholesterol, CD81 and CD9 Subcellu-
lar Localization; Influence of Cholesterol Enrichment on CD81 and
Permissiveness to P. yoelii Infection
(A) SR-BI/, hypomorphic-SR-BI, SR-BI-transgenic, and LDLR/ hepato-
cytes and SR-BI/ hepatocytes treated with MbCD-cholesterol complexes
were checked for the total cholesterol (TC) content, the free cholesterol (FC),
and esterified cholesterol (EC) contents in the whole-cell (WC) and at the
plasma membrane (PM). Values are expressed relative to those in wild-type
hepatocytes.
(B) SR-BI/ hepatocytes enriched with cholesterol by MbCD-cholesterol
complexes were tested for their permissiveness to the P. yoelii 265BY sporo-
zoite. Data are representative of three independent experiments. EEFs are
expressed relative to those in untreated wild-type hepatocytes. Means of
schizont numbers per well in controls of three independent experiments
were as follows: wtEEFs-P. yoelii, 240, 1199, and 1425.
(C) SR-BI/, hypomorphic-SR-BI, SR-BI-transgenic, and LDLR/ hepato-
cytes and SR-BI/ hepatocytes treated with MbCD-cholesterol complexes
were analyzed for CD81 and CD9 tetraspanin content. The whole-cell CD81
(CD81total), CD81 (CD81tot-mb), and CD9 (CD9tot-mb) at the plasma membrane
were quantified after staining with the MT81 or the CD9 antibody. CD81 into
enriched microdomains (CD81temd) was quantified after staining with the
MT81w antibody. Whole-cell CD81 was evaluated on permeabilized hepato-
cytes, whereas CD81tot-mb, CD81temd, and CD9tot-mb were estimated on
unpermeabilized hepatocytes. Values are expressed relative to those in
wild-type hepatocytes.
(D) Wild-type hepatocytes pretreated for 3 hr or 6 hr with a SR-BI-blocking
antibody were analyzed for the total cholesterol content (as in [A]) and CD81
expression (as in [C]). Values are expressed relative to those in untreated
wild-type hepatocytes. Cholesterol and CD81 values were normalized to the
cell density as explained in the Experimental Procedures. Results of at least
three independent experiments are expressed as mean ± standard deviation.
**p < 0.01 and *p < 0.05.Microbe 4, 283–292, September 11, 2008 ª2008 Elsevier Inc. 285
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SR-BI-deficient hepatocytes was insufficient to recover full per-
missiveness to the parasite suggests that factors other than cell
cholesterol must determine hepatocyte infectivity.
CD81 Tetraspanin Is Less Represented at the Surface
of SR-BI-Deficient Hepatocytes
Modulation of the cellular cholesterol content modifies tetraspa-
nin-microdomain organization and more specifically that of
CD81 into tetraspanin-enriched microdomains (CD81temd) at
the cell membrane (Silvie et al., 2006a). To investigate whether
CD81 expression was altered in SR-BI-deficient hepatocytes,
we evaluated CD81 localization by quantitative immunofluores-
cence assays with two different mAbs. MT81-mAb recognizes
all CD81 molecules, whereas MT81w-mAb essentially binds to
CD81temd. Total CD81 was unchanged in the different hepato-
cytes. Total CD81 at the cell surface (CD81tot-mb) and CD81temd
were reduced to about 63% ± 8% and 48% ± 12%, respectively,
in SR-BI/ hepatocytes, whereas CD9tot-mb was unaffected
(Figure 2C). Whereas CD81tot-mb and CD81temd were slightly
higher in hypomorphic-SR-BI hepatocytes than in SR-BI/
cells, they increased by 15% ± 5% and 20% ± 2%, respectively,
in SR-BI-transgenic cells as compared to wild-type cells.
Preincubation of murine hepatocytes for 6 hr with the specific
SR-BI-blocking antibody led to the fall in CD81tot-mb (65% ±
5%/nontreated cells) and CD81temd (53 ± 6%/nontreated cells)
to levels close to those in SR-BI/ cells (Figure 2D). The drop in
cell cholesterol content, CD81tot-mb, and CD81temd, was propor-
tional to that of SR-BI. To test the hypothesis that underrepre-
sentation of CD81 at the cell membrane might be specifically
due to low cholesterol content in SR-BI/ hepatocytes, we cho-
lesterol-enriched these cells with preformed MbCD-cholesterol
complexes 3 hr before CD81 analysis. Cholesterol enrichment
partially restored CD81temd (72% ± 2% of the control versus
48% ± 12% in untreated cells, i.e., a 45% improvement), but
CD81tot-mb was virtually unchanged (73% ± 6%/63% ± 8%)
(Figure 2C).
Thus, although cell cholesterol has a significant impact on the
organization of CD81 into tetraspanin-enriched microdomains,
cholesterol enrichment could not restore the full CD81tot-mb
and CD81temd in SR-BI-deficient hepatocytes. Only cells fully
expressing SR-BI and with an unaltered cholesterol content
were suitably infected by Plasmodium.
Permissiveness of C57BL/6 Hepatocytes to P. berghei
Is Essentially SR-BI/CD81 Dependent
The level of CD81-dependent permissiveness to P. berghei
infection has been reported to be target-cell specific (Silvie
et al., 2007). Here, we checked for the respective contributions
of CD81 and SR-BI to the C57BL/6 hepatocyte permissiveness.
Addition of the MT81-mAb to wild-type or SR-BI/ hepatocytes
reduced the P. berghei infection to 30% and 12% of that ob-
served in wild-type hepatocytes, respectively (Figure S3). Treat-
ment of wild-type hepatocytes with both SR-BI and MT81 Abs
reduced the permissiveness to P. berghei to 20%. These data
demonstrated that most of the P. berghei infection in C57BL/6
hepatocytes follows a SR-BI/CD81-dependent pathway.286 Cell Host & Microbe 4, 283–292, September 11, 2008 ª2008 ElSR-BI Is Involved in Schizont Development
We next assessed whether SR-BI might play a role in the hepatic
development of the parasite. Primary hepatocytes from SR-BI/
and SR-BI-transgenic mice were infected in vitro with P. yoelii
sporozoites and labeled 48 hr later with an HSP70 antibody in
order to detect the schizont forms. Fluorescence-microscopy
analysis revealed that schizont diameter was some 3-fold larger
(i.e., 27-fold more voluminous) in SR-BI-transgenic hepato-
cytes than in SR-BI/ hepatocytes (Figures 3A and 3B). More-
over, the size of schizonts was reduced in Plasmodium-infected
hepatocytes pre- or postcultured in the presence of SR-BI-block-
ing mAbs, thereby indicating that SR-BI contributed to hepatic
development of P. yoelii. Schizonts in LDLR/ hepatocytes
were similar in size to those in wild-type cells. Colabeling of
infected hepatocytes with SR-BI and HSP70 antibodies showed
Figure 3. SR-BI Is Essential for Plasmodium Liver-Stage Develop-
ment
(A) SR-BI/, hypomorphic-SR-BI, SR-BI-transgenic murine hepatocytes or
wild-type murine hepatocytes incubated with a SR-BI-blocking antibody for
54 hr (t-6h to t+48h) or 45 hr (t+3h to t+48h) were infected at t0h with P. yoelii spo-
rozoites, washed at t3h, and cultured for 45 hr. At least 450 schizonts were
measured under fluorescence microscopy. Schizont size distribution is re-
ported for 100 schizonts; mean schizont size is represented in the right corner.
Mean sizes were representative of three independent experiments performed
in triplicate. Results are expressed as mean ± standard deviation. *p < 0.05
and **p < 0.01.
(B) Plasmodium-infected SR-BI/, SR-BI-transgenic, and wild-type hepato-
cytes were labeled with the HSP70 antibody (green). Hepatocyte and schizont
nuclei were stained with DAPI (blue). Overlapping fluorescence of HSP70
antibody and DAPI is shown on the right. The arrowhead indicates schizonts.
The scale bar represents 10 mM.sevier Inc.
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tophorous vacuole (PV) membrane surrounding the schizont
(Figure 4).
Because liver-fatty acid-binding protein (L-FABP) has been
shown to be a critical host factor for successful malaria liver
stage (LS) development in HuH7 hepatoma cells (Mikolajczak
et al., 2007), we evaluated the level of the L-FABP expression
in the different hepatocytes. We observed that the level of
L-FABP expression was reduced by 50% in both SR-BI/ and
hypomorphic primary hepatocytes, whereas it was overex-
pressed by 29% ± 10% in SR-BI-transgenic hepatocytes as
compared to wild-type cells (Figure 5).
SR-BI/ Mice Are Less Susceptible to Plasmodium
Sporozoite Infection
Three-month-old male SR-BI/ mice were inoculated intrave-
nously with 4000 P. yoelii sporozoites. Blood was taken daily
and analyzed for the presence of malaria parasites in the eryth-
rocytes. Both wild-type and SR-BI/ mice developed a blood-
stage infection resulting from the complete hepatic development
of the parasite. The proportion of infected erythrocytes, as well
as the delay between inoculation and appearance of blood-
stage parasites in blood smears, was comparable in wild-type
and SR-BI/ mice (Figure 6A).
In another set of experiments, mice were inoculated with
200,000 P. yoelii sporozoites (Witney et al., 2001). At 40 hr post-
inoculation, LS parasite burden evaluated by quantitative PCR
(Carraz et al., 2006) was significantly reduced in SR-BI/
(44%) and hypomorphic-SR-BI mice (31%) (Figure 6B). Thus,
although SR-BI is not indispensable for P. yoelii infection in the
mouse, it nevertheless plays a key role in the invasion of the liver
and/or the development of the sporozoite.
DISCUSSION
Animal experiments demonstrated that SR-BI facilitated the
CD81-dependent Plasmodium infection at the liver stage and
has no influence on Plasmodium infection at the blood stage,
as it has been already demonstrated for CD81 in CD81-deficient
mice (Silvie et al., 2003). Using primary hepatocytes expressing
different levels of SR-BI and infection-inhibition assays with
SR-BI-blocking antibodies, we demonstrated that SR-BI boosts
hepatocyte permissiveness to Plasmodium entry in proportion to
the level of its own expression. In contrast to CD81 antibodies,
which are able to completely abrogate Plasmodium infection
Figure 4. SR-BI Is Not Localized at the Parasitophorous Vacuole
Membrane
Mouse primary hepatocytes were infected with P. yoelii sporozoites and
cultured for 45 hr. Schizonts were labeled with anti-HSP70 serum (red) and
SR-BI with the C11 mSR-BI antibody (green). Overlapping fluorescence is
shown on the right. The scale bar represents 10 mm.Cell Host &when added at the same time as the sporozoites, SR-BI-block-
ing antibodies must be added to hepatocytes several hours
before the parasites themselves in order to obtain optimal
inhibition. This finding suggests that SR-BI at the cell membrane
is probably not a receptor for the Plasmodium sporozoite.
Rather, inactivation of SR-BI function by SR-BI-blocking anti-
bodies probably induces a reorganization of the plasma mem-
brane; the time length required for a full SR-BI blocking effect
on Plasmodium penetration may be explained by time necessary
so that lipid-protein interactions reach a new steady state.
We thus established that SR-BI is accountable for 40% of
the total cell cholesterol content and57% of the plasma-mem-
brane cholesterol in the hepatocyte in vitro; whatever SR-BI
misses completely or is blocked at the plasma membrane. In
contrast, lack of the LDL receptor (LDLR) had no impact on
hepatocyte cholesterol content and infection efficiency in vitro.
This finding was not unexpected because SR-BI has been
shown to mediate more than 85% of the total CE uptake from
LDL- and HDL-lipoproteins in mouse hepatocytes, SR-BI being
responsible for most of the HDL-CE uptake (Rhainds and Bris-
sette, 2004; Rhainds et al., 2003; Truong et al., 2000). Thus, if
the LDLR plays any role in regulating the cholesterol content of
the hepatocyte in vitro, SR-BI (and/or other lipoprotein recep-
tors) probably plays a compensating role in cells lacking the
LDLR. On the contrary, endocytosis of cholesterol-rich LDL par-
ticles by the LDLR (or other lipoprotein receptors) could not com-
pensate for the absence of SR-BI. Previous studies have shown
Figure 5. L-FABP Expression in the Hepatocyte Is Activated
by SR-BI
Primary hepatocytes isolated from SR-BI/, hypomorphic-SR-BI, SR-BI-
transgenic, and wild-type mice were cultured for 24 hr. Total protein was ex-
tracted with 1% Triton X-100 and loaded on 12% nonreducing SDS-PAGE.
L-FABP expression level was determined by immunoblotting as described in
Experimental Procedures and normalized to tubulin expression. Data are rep-
resentative of three independent experiments. Results are expressed as mean ±
standard deviation.*p < 0.05 and **p < 0.01.Microbe 4, 283–292, September 11, 2008 ª2008 Elsevier Inc. 287
Cell Host & Microbe
Host SR-BI Enhances Plasmodium Hepatic Stagesthat the LDL-receptor-related protein (LRP) (Marshall et al., 2000)
as well as scavenger receptors such as CD36 (Sinnis and
Febbraio, 2002), SR-AI, SR-AII (Cunha-Rodrigues et al., 2006)
were not required for malaria liver stage. These data emphasize
the role of SR-BI as a major provider of cholesterol to the hepa-
tocyte and as a lipoprotein receptor involved in Plasmodium
sporozoite entry.
Some degree of cholesterol dependence for sporozoite entry
into target hepatocytes would not be surprising given that
cholesterol-depleted plasma membranes have been shown to
be less tolerant for the internalization of a number of pathogens
such as viruses, parasites (Silvie et al., 2006a), and bacteria
(Seveau et al., 2004). However, cell cholesterol was unchanged
in SR-BI-transgenic hepatocytes (probably because the flux of
cholesterol into these cells was already maximal) when Plasmo-
dium infection was enhanced in these cells. In addition, choles-
terol enrichment of SR-BI/ hepatocytes fully restored plasma-
membrane cholesterol, whereas permissiveness to Plasmodium
was increased 2-fold to only 40% of that in control cells, indi-
cating that hepatocyte permissiveness to Plasmodium is not
solely correlated to plasma-membrane cholesterol richness but
equally depends on other functions of SR-BI.
We observed that CD81tot-mb and CD81temd were underrepre-
sented at the surface of SR-BI/, hypomorphic-SR-BI hepato-
cytes and SR-BI-antibodies-treated hepatocytes, whereas
whole-cell CD81 and CD9tot-mb were unaffected. In contrast,
CD81tot-mb and CD81temd were overrepresented in SR-BI-trans-
genic cells. Cholesterol enrichment of SR-BI/ cells partially
restored CD81temd but not CD81tot-mb, whereas Plasmodium
infection was increased modestly 2-fold to only 40% of the
control. It has been previously observed that cholesterol deple-
Figure 6. Susceptibility of the SR-BI/ Mouse to P. yoelii Infection
(A) Parasitemia in blood smears: SR-BI/ (n = 5) and wild-type C57BL/6 (n = 6)
mice were inoculated intravenously by retro-orbital injection with 4 3 103 P.
yoelii sporozoites. Blood was collected daily for estimation of the parasitemia
by Giemsa staining of blood smears. The 3 day prepatent period corresponds
to the delay between inoculation and the appearance of blood-stage parasites
in blood smears. Parasitemia was defined as the percentage of infected eryth-
rocytes. Results are expressed as mean ± standard deviation. Differences be-
tween SR-BI/ and wild-type mice were not statistically significant.
(B) Analysis of liver-stage parasite burden: SR-BI/ (n = 4), hypomorphic SR-
BI (n = 6), and wild-type C57BL/6 (n = 6) mice were inoculated intravenously by
retro-orbital injection with 2 3 105 P. yoelii sporozoites. After 40 hr, liver was
harvested and P. yoelii 18S rRNA was evaluated by RT-qPCR. Results are
means within triplicates, and bars represent the median value. **p < 0.01
and *p < 0.05.288 Cell Host & Microbe 4, 283–292, September 11, 2008 ª2008 Elstion with MbCD reduces CD81temd abundance but not that of
CD81tot-mb at the surface of wild-type hepatocytes; conversely,
cholesterol replenishment with MbCD-cholesterol complexes
allows recovering of CD81temd to normal levels but does not
affect CD81tot-mb (Silvie et al., 2006a).
The fact that only cells with a normal or enhanced SR-BI ex-
pression level allowed for an optimized representation of CD81
molecules at the cell membrane, in addition to a sustained sus-
ceptibility to Plasmodium invasion, makes obvious that SR-BI or
SR-BI-related molecules, but not cellular cholesterol, oversee
the transport and/or positioning of CD81 at the cell membrane.
In addition, we demonstrated that cholesterol uptake via SR-BI
facilitates the organization of CD81 into tetraspanin-enriched
microdomains at the plasma membrane. Cholesterol enrichment
strongly enhanced permissivity to both Plasmodium invasion
and CD81temd, but not CD81tot-mb. This correlation clearly sug-
gests that CD81temd might represent a highly permissive form
of CD81 that would allow the formation of a membrane that is
highly permissive to invasion by pathogens whose internalization
is CD81 dependent. In such a scheme, enhancement of mem-
brane cholesterol might displace an equilibrium toward this
highly permissive membrane and away from a less permissive
membrane containing CD81 molecules not incorporated into
CD81temd (Figure 7).
In summary, we have established that SR-BI at the hepatocyte
membrane facilitates the positioning of CD81 at the cell surface
as well the organization of CD81 into an arrangement highly
permissive to Plasmodium sporozoite entry. Such a relocation
of CD81 after a reorganization of the membrane is not without
precedent. Ceramide enrichment of the plasma membrane in
hepatoma cells induces CD81 internalization (50%) and strongly
reduces HCV entry, whereas the cell cholesterol and SR-BI at the
cell surface are unaffected (Voisset et al., 2008).
The hypothesis that SR-BI is a HCV coreceptor is mostly
based on HCV-infection-inhibition assays using SR-BI inhibitors,
SR-BI-blocking antibodies (Bartosch et al., 2003; Kapadia et al.,
2007), SR-BI-siRNA (Kapadia et al., 2007), and natural SR-BI’s
ligands (HDL and VLDL) (Maillard et al., 2006; Voisset et al.,
2005) or on molecular interaction studies between sE2 (a trun-
cated form of the HCV glycoprotein E2) and SR-BI molecules
(Scarselli et al., 2002). SR-BI overexpression enhanced HCV in-
fectivity, thereby suggesting that endogeneous levels of SR-BI
limit HCV infection (Grove et al., 2007). However, HCV-infec-
tion-inhibition assays have rarely explored the consequences
of the blockage of SR-BI functions at the cell and/or plasma-
membrane level and SR-BI-sE2 interaction studies might not
reflect the reality of native E2-SR-BI interaction as it occurs dur-
ing virus entry. In contrast, other authors have postulated that
SR-BI is not a classical receptor to which the virus binds, but
that it may be a molecule with the capacity to modulate the lipid
composition of the plasma membrane (Grove et al., 2007; Kapa-
dia et al., 2007). It is thus tempting to extrapolate our conclusions
to the HCV invasion model and to assume that the clustering of
CD81 (which is SR-BI and cholesterol dependent) in tetraspanin-
enriched microdomains is also essential to render hepatocytes
permissive to HCV entry. In this scheme, SR-BI would act as a
modulator of the CD81-dependent HCV entry.
Schizonts in infected SR-BI/ hepatocytes were some 27
folds smaller than in SR-BI-transgenic hepatocytes. The size ofevier Inc.
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hepatocytes postcultured in the presence of SR-BI-blocking
mAbs. SR-BI-deficient cells nevertheless permitted formation
of fully infectious merozoites. In the early steps of the invasion,
the parasite is enclosed in a parasitophorous vacuole (PV), which
is essentially derived from the host plasma membrane and most
of the PV membrane (PVM) components, including the choles-
terol molecules, being of hepatocytic origin. Further PV develop-
ment requires the recruitment of cholesterol from host cell
compartments because, like many protozoa, Plasmodium can-
not synthesize sterols de novo (Bano et al., 2007; Coppens
et al., 2000). As shown above, the LDLR has no impact on the
entry and development of Plasmodium, and such a finding
strengthens the specific role of SR-BI in the process of the Plas-
modium infection. Thus, the Plasmodium parasite may reroute
and sequester host cell cholesterol collected essentially through
SR-BI (but not or only poorly through LDLR) for PVM reorganiza-
tion (Bano et al., 2007) and promotion of the PV growth.
On the other hand, we observed that L-FABP was underex-
pressed in cells lacking SR-BI and overexpressed in SR-BI-
transgenic cells. In hepatocytes, L-FABP is the main cytoplasmic
carrier of fatty acids and free cholesterol, both being products of
CE hydrolysis, acting as a shuttle for storage as well as for deliv-
ery to the intracellular destination. Our finding is consistent with
the previous observation that L-FABP is upregulated in HepG2
cells overexpressing SR-BI (Rhainds et al., 2004). This
Figure 7. A Mechanistic Pathway of the CD81-Dependent Hepatocyte Invasion by Plasmodium
This scheme shows the relationships between SR-BI, cell cholesterol, organization of CD81 into tetraspanin-enriched microdomains at the plasma membrane,
and permissiveness of the hepatocyte to Plasmodium infection. SR-BI at the plasma membrane acts as a cholesterol provider to the hepatocyte via selective
HDL-cholesteryl ester uptake. The cholesterol increase at the plasma membrane facilitates the organization of CD81 into tetraspanin-enriched microdomains,
thereby allowing the formation of a plasma membrane highly permissive to the sporozoite penetration. Moreover, SR-BI or SR-BI-related molecules permit the
transport and/or positioning of CD81 molecules at the cell membrane, boosting once more the constitution of a highly permissive membrane and the hepatocyte
permissiveness to CD81-dependent pathogens. The sporozoite of Plasmodium gets through the highly permissive membrane, internalizes in the target hepato-
cyte via the formation of a parasitophorous vacuole (PV) and develops close to the cell nucleus where it interacts with the endoplasmic reticulum. Concomitantly,
SR-BI or SR-BI-related molecules such as fatty acids activate the expression of the L-FABP gene. L-FABP probably localizes in the endoplasmic reticulum sur-
rounding the PV where it might then be sequestered at the PVM to import cholesterol and fatty acids of cytosolic origin into the PV, thus allowing the development
of Plasmodium exoerythrocytic forms.
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due to SR-BI-mediated CE-selective uptake and hydrolysis, that
may reach a threshold level at which L-FABP and other genes in-
volved in fatty-acid metabolism are induced. In addition, L-FABP
was shown to be necessary for successful LS development (Mi-
kolajczak et al., 2007). After internalization of the parasite, the
PVM undergoes modifications by insertion of proteins of para-
sitic origin. Some of these proteins are believed to establish
a controlled exchange interface with the host cell. One of
them, UIS3 (upregulated in infective sporozoites gene 3), which
was found to be essential for LS growth and development, has
recently been reported to interact directly with L-FABP (Mikolajc-
zak et al., 2007).
Considered together, these findings allowed us to establish
the mechanistic basis of the Plasmodium invasion CD81-depen-
dent pathway (Figure 7). SR-BI at the plasma membrane acts as
a provider of cholesterol to the hepatocyte membrane, thereby
facilitating reorganization of the hepatocyte membrane into
one highly permissive to the entry of the Plasmodium sporozoite.
Moreover, SR-BI or SR-BI-related molecules activate the trans-
port and/or positioning of CD81 molecules at the cell membrane,
boosting once more the organization of CD81 into highly permis-
sive tetraspanin-enriched microdomains and subsequently
boosting hepatocyte permissiveness to the CD81-dependent
pathogen. The sporozoite of Plasmodium takes advantage of
these permissive domains to enter the target hepatocyte via
the formation of a parasitophorous vacuole and develops close
to the nuclear region where it interacts with the ER. SR-BI or
SR-BI-related molecules such as fatty acids activate the expres-
sion of the L-FABP protein. L-FABP in the ER surrounding the PV
might then be sequestered by the plasmodial UIS3 protein at the
PVM to import cholesterol and fatty acids of cytosolic origin into
the PV, thus allowing the development of Plasmodium exoeryth-
rocytic forms. Comparing the patterns of the hepatocyte infec-
tion by Plasmodium and HCV, we hypothesize that the first steps
of the CD81-dependent pathway for Plasmodium infection are
potentially relevant for HCV entry.
EXPERIMENTAL PROCEDURES
Antibodies
Rabbit polyclonal serum raised against hSR-B1 was generated as described
previously (Maillard et al., 2006). Human mAb directed against mSR-BI (C11)
(Catanese et al., 2007) was the gift of Dr. Alessandra Vitelli (IRBM, Pomezia,
Italia). Murine MT81, MT81w, and 4.1 F12 (anti-mCD9) mAbs were kindly pro-
vided by Dr. Eric Rubinstein (Silvie et al., 2006a). MT81 mAb recognizes all
CD81 molecules, whereas MT81w mAb binds to CD81 molecules associated
with tetraspanin-enriched microdomains. Murine anti-L-FABP and anti-tubulin
mAbs were purchased from Abcam (Paris, France). The mouse polyclonal
serum raised against the P. falciparum heat shock protein 70 (HSP70) was pre-
pared with a recombinant HSP70, a gift from D. Mattei (Institut Pasteur, Paris);
this serum crossreacts with the homologous protein of P. yoelii and P. berghei
(Renia et al., 1990).
Mice and Parasites
All animal care and procedures were performed in accordance with institu-
tional guidelines and European regulations. Experiments were conducted
with SR-BI/, hypomorphic-SR-BI (Huby et al., 2006) and SR-BI transgenic
male mice (Bietrix et al., 2006) aged 13–18 weeks; age- and gender-matched
C57BL/6J mice (from Janvier, France) were wild-type controls. Hypomorphic-
SR-BI hepatocytes weakly express SR-BI (10% of the level in wild-type
cells), whereas SR-BI-transgenic hepatocytes display 3-fold SR-BI overex-290 Cell Host & Microbe 4, 283–292, September 11, 2008 ª2008 Elpression. B6.129S7-Ldlrtm1Her/J (LDL-R-deficient) mice were purchased
from the Jackson Laboratory (Bar Harbor, Maine, USA). P. yoelii (265BY
and 17XNL-clone1.1 strains), P. berghei (ANKA strain), and P. falciparum
(NF54 strain) sporozoites were obtained by dissection of infected Anopheles
stephensi mosquito salivary glands.
In Vivo Quantification of Malaria Blood-Stage Infection
Wild-type (n = 6) and SR-BI/ (n = 5) male mice were infected by retro-orbital
injection with 43 103 P. yoelii 265BY sporozoites. Parasites were enumerated
by blinded microscopic examination of Giemsa-stained tail-blood smears
collected from day 2 to day 14 postinoculation.
Real-Time PCR Quantification of Liver-Stage Parasite Burden
Wild-type (n = 6), SR-B1/ (n = 4) and hypomorphic-SR-BI (n = 6) male mice
were infected by retro-orbital injection with 23 105 P. yoelii 265BY sporozoites
and sacrificed 40 hr after inoculation. Livers were harvested and homogenized
with a Polytron homogenizer, and total RNA was isolated with the Micro-to-
Midi Total RNA Purification System (Invitrogen). The detection and quantifica-
tion of the LS parasite load was performed on the corresponding total cDNAs,
as detailed previously (Carraz et al., 2006). Amplified P. yoelii 18S sequences
were normalized to b-actin. All TaqMan test samples were performed in
triplicate.
In Vitro Plasmodium Infection and Inhibition Assays
Primary mouse hepatocytes were isolated as previously described (Renia
et al., 1990), seeded in eight-well Lab-Tek plastic chamber slides (Nalge
Nunc International, Cergy Pontoise, France) at a density of 105 cells per well
or 4 3 104 cells per well in 96-well microplates and cultured at 37C in 5%
CO2 in William’s E medium (Invitrogen, GIBCO) supplemented with 2% peni-
cillin-streptomycin, 1% sodium pyruvate, 1% L-glutamine, 1% insulin-trans-
ferrin-selenium, and 10% fetal bovine serum (Invitrogen, GIBCO).
Human liver fragments were collected after informed consent provided from
patients undergoing a partial hepatectomy. The collection and use of these
tissues were undertaken in accordance with French government ethical regu-
lations. Primary human hepatocytes were isolated from healthy parts of the
liver biopsies as previously described (Carraz et al., 2006), seeded at a density
of 83 104 cells in 96-well microplates precoated with rat tail collagen I (Becton
Dickinson, Le Pont de Claix, France), and cultured at 37C in 5% CO2, in the
same culture medium as above, supplemented with 107 M dexamethasone
(Sigma, Saint Quentin Fallavier, France). Mouse and human hepatocytes
were cultured for 24 hr before infection.
For infection-inhibition assays in 96-well plates, the plates were centrifuged
after inoculation of 2.5 3 104 Plasmodium sporozoites to allow the parasite to
come immediately into contact with the target cells. After sporozoite penetra-
tion into hepatocytes for 3 hr at 37C, cultures were washed and further incu-
bated in fresh medium for 2 to 5 days (forP. yoelii orP. falciparum, respectively)
until EEF quantification. Anti-hSR-B1-antibody (1:100), C11-mAb (5 mg/ml) or
MT81 (20 mg/ml) were incubated with human or murine hepatocytes, respec-
tively, for different periods of time, before or after sporozoite inoculation.
Parasite Quantification by Immunofluorescence Analysis
After fixation of the cultures with cold methanol, EEFs were stained with the
anti-HSP70 serum (Renia et al., 1990) and revealed with FITC-conjugated
(Sigma) or Alexa-Fluor-680-conjugated (Invitrogen, Molecular Probes) goat
anti-mouse immunoglobulin and counted under a fluorescence microscope
or with the Odyssey Infrared Imaging System (LI-COR Biosciences) as de-
scribed previously (Gego et al., 2006). Nuclei were stained with 1 mg/ml diami-
dino-phenyl-indole (DAPI; Sigma). All assays were performed in triplicate.
Quantification of extracellular and intracellular parasites was carried out with
double immunostaining as described before (Renia et al., 1988; Silvie et al.,
2003).
Cholesterol Enrichment, Cholesterol Analysis,
and CD81 Quantification
Mouse hepatocytes were seeded in 6-well or 96-well microplates at a density
of 1.4 3 106 or 4 3 104 cells per well for plasma-membrane isolation or other
experiments, respectively. Plasma membranes were prepared essentially as
described before (Hubbard et al., 1983). Protease inhibitors (PMSF, INH)sevier Inc.
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was achieved by incubating SR-BI/ hepatocytes with a 1:10 (mol/mol)
complex of cholesterol (Sigma) and methyl-b cyclodextrin (Sigma; MbCD) for
10 min essentially as described previously (Silvie et al., 2006a). Cholesterol-en-
riched hepatocytes were then washed with a complete medium and cultured
for 3 hr before cellular cholesterol analysis. Total cell cholesterol, free choles-
terol, and cholesteryl esters were determined with the Amplex Red cholesterol
kit (Invitrogen, Molecular Probes) according to the manufacturer’s instructions.
For CD9 and CD81 quantification, after fixation with 4% paraformaldehyde in
PBS, cells were permeabilized or not with saponin 0.1% in PBS, labeled with
saturating concentration of CD9, MT81, or MT81w mAb (1:100) (Silvie et al.,
2006a), and revealed with a goat anti-mouse IgG FITC conjugate (Sigma).
Cell density was evaluated with DAPI and used to normalize cholesterol and
for CD9 and CD81 analysis. Well fluorescence was counted with Packard
fusion.
Western Blotting and Cell Immunofluorescence
Mouse primary hepatocytes cultured for 24 hr were lysed at 4C for 30 min in
30 mM Tris (pH 7.4), 150 mM NaCl, 0.02% NaN3, protease inhibitors (PMSF,
INH), and 1% Triton X-100. Murine L-FABP was analyzed by western blotting
with a mouse anti-L-FABP mAb (1/500) and then a goat anti-mouse Alexa Fluor
680 (Invitrogen) (1:15000). Monoclonal mouse antitubulin (1:5000) was used as
a standard. Data were acquired and quantified with an Odyssey Infrared
Imaging System. In SR-BI immunostainings, schizonts were stained with the
anti-HSP70 serum and were revealed with TRITC-conjugate goat anti-mouse
immunoglobulin, whereas SR-BI was labeled with C11 mAb (5 mg/ml) and then
FITC-conjugate goat anti-human immunoglobulin.
Statistical Analysis
All data were analyzed for statistical significance with the one-way ANOVA and
then the Tukey multiple comparison test.
SUPPLEMENTAL DATA
Supplemental Data include three figures and Supplemental References and
can be found with this article online at http://www.cellhostandmicrobe.com/
cgi/content/full/4/3/283/DC1/.
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